Kiniksa inks licensing deal to take a Regeneron castoff into Asian markets

After digging through Regeneron’s trash bin, Kiniksa has managed to put together a tiny run with the aging drug Arcalyst in recent years. Now, the company will look to break through in Asian markets.

Huadong Medicine will pay $22 million upfront and a potential $640 million in downstream milestones to exclusively license Kiniksa’s Arcalyst, an IL-1α and IL-1β blocker, and Covid-19 antibody candidate mavrilimumab in Asian markets not including Japan, the partners said Wednesday.